Demographic and clinical characteristics of patients with systemic lupus erythematosus.

Values are median (interquartile range, IQR) unless stated otherwise; s.d., standard deviation; n.a., not applicable. SLE, systemic lupus erythematosus; Group 1) Patients with inactive disease (SLEDAI 4) who had received or are currently on immunosuppressants. SLEDAI, systemic lupus erythematosus disease activity index; SLICC, Systemic Lupus International Collaborating Clinics Score;┼“Never” refers to SLE patients never be given treatment of immunosuppressants [prednisolone, hydroxychloroquine, azathioprine, cyclophosphamide (oral or IV), cyclosporin A and mycophenolate mofetil] since the diagnosis of SLE or within recent 10 years;┼┼“Ever” refer to use of immunosuppressants since the diagnosis of SLE.┼┼┼“Flare” is defined as increase in the SLEDAI score by 3 or more;&p&&p&&&p*p**p***p#p##p###p